JP2012508017A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012508017A5 JP2012508017A5 JP2011535651A JP2011535651A JP2012508017A5 JP 2012508017 A5 JP2012508017 A5 JP 2012508017A5 JP 2011535651 A JP2011535651 A JP 2011535651A JP 2011535651 A JP2011535651 A JP 2011535651A JP 2012508017 A5 JP2012508017 A5 JP 2012508017A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- seq
- acid sequence
- chain variable
- variable region
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 229
- 210000004602 germ cell Anatomy 0.000 claims 66
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 41
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 41
- 238000006467 substitution reaction Methods 0.000 claims 37
- 150000001413 amino acids Chemical class 0.000 claims 23
- 125000000539 amino acid group Chemical group 0.000 claims 20
- 102000040430 polynucleotide Human genes 0.000 claims 16
- 108091033319 polynucleotide Proteins 0.000 claims 16
- 239000002157 polynucleotide Substances 0.000 claims 16
- 210000004027 cell Anatomy 0.000 claims 14
- 101000839682 Homo sapiens Immunoglobulin heavy variable 4-34 Proteins 0.000 claims 13
- 102100028306 Immunoglobulin heavy variable 4-34 Human genes 0.000 claims 13
- 101001091242 Homo sapiens Immunoglobulin kappa joining 1 Proteins 0.000 claims 11
- 102100034892 Immunoglobulin kappa joining 1 Human genes 0.000 claims 11
- 101000839684 Homo sapiens Immunoglobulin heavy variable 4-31 Proteins 0.000 claims 10
- 102100028310 Immunoglobulin heavy variable 4-31 Human genes 0.000 claims 10
- 102220353972 c.292T>G Human genes 0.000 claims 10
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 9
- 101000872077 Homo sapiens Delta-like protein 4 Proteins 0.000 claims 9
- 101000998947 Homo sapiens Immunoglobulin heavy variable 1-46 Proteins 0.000 claims 9
- 102100036888 Immunoglobulin heavy variable 1-46 Human genes 0.000 claims 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 9
- 102220587343 Cellular tumor antigen p53_S99P_mutation Human genes 0.000 claims 8
- 101001138133 Homo sapiens Immunoglobulin kappa variable 1-5 Proteins 0.000 claims 7
- 102100020769 Immunoglobulin kappa variable 1-5 Human genes 0.000 claims 7
- 239000000203 mixture Substances 0.000 claims 7
- 102220228928 rs1064793060 Human genes 0.000 claims 7
- 102220040126 rs371657037 Human genes 0.000 claims 7
- 101000989062 Homo sapiens Immunoglobulin heavy variable 5-51 Proteins 0.000 claims 6
- 102100029414 Immunoglobulin heavy variable 5-51 Human genes 0.000 claims 6
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims 6
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 6
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims 6
- 239000012634 fragment Substances 0.000 claims 6
- 108090000765 processed proteins & peptides Proteins 0.000 claims 6
- 102200115585 rs539699299 Human genes 0.000 claims 6
- 102220046035 rs587782586 Human genes 0.000 claims 6
- 239000013598 vector Substances 0.000 claims 6
- 102220495789 Alkaline ceramidase 1_S28A_mutation Human genes 0.000 claims 5
- 102220590441 Epoxide hydrolase 3_S30D_mutation Human genes 0.000 claims 5
- 102220554706 Holliday junction recognition protein_S30T_mutation Human genes 0.000 claims 5
- 101000956885 Homo sapiens Immunoglobulin lambda variable 2-14 Proteins 0.000 claims 5
- 102100038429 Immunoglobulin lambda variable 2-14 Human genes 0.000 claims 5
- 239000005557 antagonist Substances 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 5
- 102000044457 human DLL4 Human genes 0.000 claims 5
- 238000000034 method Methods 0.000 claims 5
- 229920001184 polypeptide Polymers 0.000 claims 5
- 102000004196 processed proteins & peptides Human genes 0.000 claims 5
- 102200006408 rs746834149 Human genes 0.000 claims 5
- 102220123567 rs886043442 Human genes 0.000 claims 5
- VEEGZPWAAPPXRB-BJMVGYQFSA-N (3e)-3-(1h-imidazol-5-ylmethylidene)-1h-indol-2-one Chemical compound O=C1NC2=CC=CC=C2\C1=C/C1=CN=CN1 VEEGZPWAAPPXRB-BJMVGYQFSA-N 0.000 claims 4
- 102100033553 Delta-like protein 4 Human genes 0.000 claims 4
- 101000978126 Homo sapiens Immunoglobulin lambda variable 8-61 Proteins 0.000 claims 4
- 102100023752 Immunoglobulin lambda variable 8-61 Human genes 0.000 claims 4
- 239000004037 angiogenesis inhibitor Substances 0.000 claims 4
- 229940121369 angiogenesis inhibitor Drugs 0.000 claims 4
- 208000035475 disorder Diseases 0.000 claims 4
- 102220265335 rs139105272 Human genes 0.000 claims 4
- 102220259666 rs550137245 Human genes 0.000 claims 4
- 102220562905 Bromodomain-containing protein 1_I51K_mutation Human genes 0.000 claims 3
- 102220597389 G0/G1 switch protein 2_R54A_mutation Human genes 0.000 claims 3
- 101001079285 Homo sapiens Immunoglobulin heavy joining 1 Proteins 0.000 claims 3
- 101000998952 Homo sapiens Immunoglobulin heavy variable 1-3 Proteins 0.000 claims 3
- 101000989060 Homo sapiens Immunoglobulin heavy variable 6-1 Proteins 0.000 claims 3
- 101001138128 Homo sapiens Immunoglobulin kappa variable 1-12 Proteins 0.000 claims 3
- 101001047617 Homo sapiens Immunoglobulin kappa variable 3-11 Proteins 0.000 claims 3
- 101001047619 Homo sapiens Immunoglobulin kappa variable 3-20 Proteins 0.000 claims 3
- 101001134437 Homo sapiens Immunoglobulin lambda joining 1 Proteins 0.000 claims 3
- 102100028078 Immunoglobulin heavy joining 1 Human genes 0.000 claims 3
- 102100036886 Immunoglobulin heavy variable 1-3 Human genes 0.000 claims 3
- 102100029416 Immunoglobulin heavy variable 6-1 Human genes 0.000 claims 3
- 102100020773 Immunoglobulin kappa variable 1-12 Human genes 0.000 claims 3
- 102100022955 Immunoglobulin kappa variable 3-11 Human genes 0.000 claims 3
- 102100022964 Immunoglobulin kappa variable 3-20 Human genes 0.000 claims 3
- 102100034172 Immunoglobulin lambda joining 1 Human genes 0.000 claims 3
- 102220580970 Induced myeloid leukemia cell differentiation protein Mcl-1_I50T_mutation Human genes 0.000 claims 3
- 102220601218 Microtubule-associated protein tau_T30A_mutation Human genes 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 102000005650 Notch Receptors Human genes 0.000 claims 3
- 108010070047 Notch Receptors Proteins 0.000 claims 3
- 102220613568 Potassium voltage-gated channel subfamily H member 2_F29A_mutation Human genes 0.000 claims 3
- 102220509115 Sphingosine 1-phosphate receptor 1_Y97V_mutation Human genes 0.000 claims 3
- 230000004913 activation Effects 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 230000000694 effects Effects 0.000 claims 3
- 210000003527 eukaryotic cell Anatomy 0.000 claims 3
- 239000013604 expression vector Substances 0.000 claims 3
- 210000001236 prokaryotic cell Anatomy 0.000 claims 3
- 102200075235 rs118204106 Human genes 0.000 claims 3
- 102220043120 rs144094344 Human genes 0.000 claims 3
- 102220012182 rs373164247 Human genes 0.000 claims 3
- 102200094314 rs74315399 Human genes 0.000 claims 3
- 102100036312 5-hydroxytryptamine receptor 1E Human genes 0.000 claims 2
- 102220554162 APC membrane recruitment protein 1_I34A_mutation Human genes 0.000 claims 2
- 102220625606 Ankyrin repeat domain-containing protein 2_S94G_mutation Human genes 0.000 claims 2
- 102220547840 Apoptosis-associated speck-like protein containing a CARD_L25Q_mutation Human genes 0.000 claims 2
- 102220475086 Bifunctional arginine demethylase and lysyl-hydroxylase JMJD6_L90A_mutation Human genes 0.000 claims 2
- 102220523639 C-C motif chemokine 2_S50Q_mutation Human genes 0.000 claims 2
- 102220587363 Cellular tumor antigen p53_S94L_mutation Human genes 0.000 claims 2
- 102220566212 Cyclic AMP-dependent transcription factor ATF-7_T51A_mutation Human genes 0.000 claims 2
- 102220566211 Cyclic AMP-dependent transcription factor ATF-7_T51D_mutation Human genes 0.000 claims 2
- 102220632031 Decorin_D54A_mutation Human genes 0.000 claims 2
- 102220632043 Decorin_D56A_mutation Human genes 0.000 claims 2
- 102220526112 Dihydrofolate reductase_M92F_mutation Human genes 0.000 claims 2
- 102220526111 Dihydrofolate reductase_M92L_mutation Human genes 0.000 claims 2
- 102220519145 E3 ubiquitin/ISG15 ligase TRIM25_V89G_mutation Human genes 0.000 claims 2
- 102220475128 Ectodysplasin-A_W33A_mutation Human genes 0.000 claims 2
- 102220559985 Epsilon-sarcoglycan_M92T_mutation Human genes 0.000 claims 2
- 102220511662 Heme oxygenase 1_S58A_mutation Human genes 0.000 claims 2
- 102220588493 Hemoglobin subunit beta_T51K_mutation Human genes 0.000 claims 2
- 102220483804 High mobility group protein B1_Y97H_mutation Human genes 0.000 claims 2
- 102220471962 Histone deacetylase 7_S55W_mutation Human genes 0.000 claims 2
- 101000998951 Homo sapiens Immunoglobulin heavy variable 1-8 Proteins 0.000 claims 2
- 101001047618 Homo sapiens Immunoglobulin kappa variable 3-15 Proteins 0.000 claims 2
- 101000978120 Homo sapiens Probable non-functional immunoglobulin lambda variable 11-55 Proteins 0.000 claims 2
- 101001005499 Homo sapiens Probable non-functional immunoglobulin lambda variable 5-48 Proteins 0.000 claims 2
- 101001115218 Homo sapiens Ubiquitin-40S ribosomal protein S27a Proteins 0.000 claims 2
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims 2
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims 2
- 102220511640 Immunoglobulin heavy joining 1_S30L_mutation Human genes 0.000 claims 2
- 102100036885 Immunoglobulin heavy variable 1-8 Human genes 0.000 claims 2
- 102100022965 Immunoglobulin kappa variable 3-15 Human genes 0.000 claims 2
- 102220478979 Interleukin-4 receptor subunit alpha_Y99A_mutation Human genes 0.000 claims 2
- 102220497573 Leukotriene B4 receptor 1_N52A_mutation Human genes 0.000 claims 2
- 102220486635 Mannose-1-phosphate guanyltransferase beta_S56A_mutation Human genes 0.000 claims 2
- 102220503895 Meiotic recombination protein REC8 homolog_S92V_mutation Human genes 0.000 claims 2
- 102220637445 Mitochondrial genome maintenance exonuclease 1_M92A_mutation Human genes 0.000 claims 2
- 102220537350 Neural retina-specific leucine zipper protein_S50L_mutation Human genes 0.000 claims 2
- 102220502536 Platelet-activating factor acetylhydrolase IB subunit alpha2_G55E_mutation Human genes 0.000 claims 2
- 102100023451 Probable non-functional immunoglobulin lambda variable 11-55 Human genes 0.000 claims 2
- 102100025167 Probable non-functional immunoglobulin lambda variable 5-48 Human genes 0.000 claims 2
- 102220569743 Programmed cell death protein 6_Y91A_mutation Human genes 0.000 claims 2
- 102220465274 Purine nucleoside phosphorylase LACC1_Y52A_mutation Human genes 0.000 claims 2
- 102220612295 Putative coiled-coil domain-containing protein 144 N-terminal-like_S55D_mutation Human genes 0.000 claims 2
- 102220615003 RELT-like protein 2_G100L_mutation Human genes 0.000 claims 2
- 102220573220 Ras-related protein Ral-A_S50W_mutation Human genes 0.000 claims 2
- -1 S100H Proteins 0.000 claims 2
- 102220509670 SAM and SH3 domain-containing protein 1_Y31A_mutation Human genes 0.000 claims 2
- 102220471545 Single-stranded DNA cytosine deaminase_S26A_mutation Human genes 0.000 claims 2
- 102220471558 Single-stranded DNA cytosine deaminase_S94A_mutation Human genes 0.000 claims 2
- 102220578494 Suppressor of fused homolog_R95A_mutation Human genes 0.000 claims 2
- 102220522291 THAP domain-containing protein 1_S31A_mutation Human genes 0.000 claims 2
- 102220536914 Transcription factor JunD_P33A_mutation Human genes 0.000 claims 2
- 102220469971 Tryptase delta_Y32A_mutation Human genes 0.000 claims 2
- 102220534415 Tyrosine-protein phosphatase non-receptor type 1_S50D_mutation Human genes 0.000 claims 2
- 102100023341 Ubiquitin-40S ribosomal protein S27a Human genes 0.000 claims 2
- 102220474577 Ubiquitin-conjugating enzyme E2 D1_S94E_mutation Human genes 0.000 claims 2
- 102220546632 Voltage-dependent L-type calcium channel subunit beta-2_S55N_mutation Human genes 0.000 claims 2
- 102220532163 WW domain-binding protein 11_I51S_mutation Human genes 0.000 claims 2
- 239000002253 acid Substances 0.000 claims 2
- 229960000397 bevacizumab Drugs 0.000 claims 2
- 102220361905 c.148A>C Human genes 0.000 claims 2
- 102220352372 c.148T>G Human genes 0.000 claims 2
- 238000009472 formulation Methods 0.000 claims 2
- 102200006655 rs104894230 Human genes 0.000 claims 2
- 102200041211 rs104894459 Human genes 0.000 claims 2
- 102220209728 rs1057523598 Human genes 0.000 claims 2
- 102220216591 rs1060503509 Human genes 0.000 claims 2
- 102220230165 rs1064793071 Human genes 0.000 claims 2
- 102220003317 rs137852699 Human genes 0.000 claims 2
- 102220187877 rs143008696 Human genes 0.000 claims 2
- 102220328414 rs1453134737 Human genes 0.000 claims 2
- 102220280629 rs1555085496 Human genes 0.000 claims 2
- 102220276093 rs1555932427 Human genes 0.000 claims 2
- 102200079914 rs193302884 Human genes 0.000 claims 2
- 102200097284 rs199472834 Human genes 0.000 claims 2
- 102200097263 rs199472844 Human genes 0.000 claims 2
- 102200133096 rs199473644 Human genes 0.000 claims 2
- 102220011589 rs200960071 Human genes 0.000 claims 2
- 102220011222 rs281865133 Human genes 0.000 claims 2
- 102220006845 rs281874706 Human genes 0.000 claims 2
- 102200043447 rs281875243 Human genes 0.000 claims 2
- 102200043446 rs281875252 Human genes 0.000 claims 2
- 102200110749 rs28941476 Human genes 0.000 claims 2
- 102200082820 rs33960931 Human genes 0.000 claims 2
- 102220005308 rs33960931 Human genes 0.000 claims 2
- 102220015169 rs397517383 Human genes 0.000 claims 2
- 102220044474 rs587781329 Human genes 0.000 claims 2
- 102220045199 rs587781908 Human genes 0.000 claims 2
- 102220094065 rs587782586 Human genes 0.000 claims 2
- 102200030476 rs615942 Human genes 0.000 claims 2
- 102220169097 rs61730848 Human genes 0.000 claims 2
- 102220289621 rs63750336 Human genes 0.000 claims 2
- 102200101937 rs72554349 Human genes 0.000 claims 2
- 102220337697 rs72555390 Human genes 0.000 claims 2
- 102200006406 rs746834149 Human genes 0.000 claims 2
- 102220224491 rs765799649 Human genes 0.000 claims 2
- 102220234886 rs778952116 Human genes 0.000 claims 2
- 102220068510 rs794727508 Human genes 0.000 claims 2
- 102220094066 rs876659747 Human genes 0.000 claims 2
- 102200153318 rs913934445 Human genes 0.000 claims 2
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 claims 2
- 102220496020 5-hydroxytryptamine receptor 3B_N52S_mutation Human genes 0.000 claims 1
- 102220497137 5-hydroxytryptamine receptor 3B_S30G_mutation Human genes 0.000 claims 1
- 102220497105 5-hydroxytryptamine receptor 3B_T56A_mutation Human genes 0.000 claims 1
- 102220485321 ATP-dependent DNA/RNA helicase DHX36_G55L_mutation Human genes 0.000 claims 1
- 102220511774 Adenylosuccinate lyase_S31N_mutation Human genes 0.000 claims 1
- 108700028369 Alleles Proteins 0.000 claims 1
- 102220479279 Anoctamin-3_N52T_mutation Human genes 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 102220617612 B-cell acute lymphoblastic leukemia-expressed protein_N93H_mutation Human genes 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 102220518361 Casein kinase I isoform gamma-2_Y33A_mutation Human genes 0.000 claims 1
- 102220569940 Cytochrome P450 1B1_S28W_mutation Human genes 0.000 claims 1
- 102220632024 Decorin_N53A_mutation Human genes 0.000 claims 1
- 102220510722 Dual specificity tyrosine-phosphorylation-regulated kinase 2_S98G_mutation Human genes 0.000 claims 1
- 201000009273 Endometriosis Diseases 0.000 claims 1
- 102220529131 Eukaryotic translation initiation factor 2 subunit 1_S53P_mutation Human genes 0.000 claims 1
- 108010008177 Fd immunoglobulins Proteins 0.000 claims 1
- 102220607093 Gap junction beta-1 protein_S52P_mutation Human genes 0.000 claims 1
- 102220619583 Glycine receptor subunit alpha-1_G55V_mutation Human genes 0.000 claims 1
- 102220543692 Guanine nucleotide-binding protein G(s) subunit alpha isoforms XLas_N53G_mutation Human genes 0.000 claims 1
- 102220511665 Heme oxygenase 1_S76A_mutation Human genes 0.000 claims 1
- 102220537095 Hemoglobin subunit epsilon_N53H_mutation Human genes 0.000 claims 1
- 102220491788 High mobility group protein B1_S53E_mutation Human genes 0.000 claims 1
- 101001008293 Homo sapiens Immunoglobulin kappa variable 2D-40 Proteins 0.000 claims 1
- 102100027409 Immunoglobulin kappa variable 2D-40 Human genes 0.000 claims 1
- 102220631528 Krueppel-like factor 13_G55W_mutation Human genes 0.000 claims 1
- 102220497574 Leukotriene B4 receptor 1_N52Q_mutation Human genes 0.000 claims 1
- 102220642036 Lipoma-preferred partner_S76N_mutation Human genes 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 102220482828 Mitochondrial coenzyme A diphosphatase NUDT8_E96A_mutation Human genes 0.000 claims 1
- 102220612416 Mitogen-activated protein kinase kinase kinase 1_S92N_mutation Human genes 0.000 claims 1
- 102220631334 NCK-interacting protein with SH3 domain_S92G_mutation Human genes 0.000 claims 1
- 102220537824 Nebulette_S99A_mutation Human genes 0.000 claims 1
- 206010029113 Neovascularisation Diseases 0.000 claims 1
- 102220572954 Netrin receptor UNC5C_S28F_mutation Human genes 0.000 claims 1
- 102220592550 Neuroserpin_S52R_mutation Human genes 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 102220510219 Poly(A)-specific ribonuclease PNLDC1_S31G_mutation Human genes 0.000 claims 1
- 102220559090 Potassium voltage-gated channel subfamily E member 1_S28T_mutation Human genes 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 102220467908 Protein Dok-7_S30W_mutation Human genes 0.000 claims 1
- 102220519841 Putative neutrophil cytosol factor 1B_S30P_mutation Human genes 0.000 claims 1
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 1
- 102220596972 Ski oncogene_S31L_mutation Human genes 0.000 claims 1
- 102220606007 Sorting nexin-10_Y32S_mutation Human genes 0.000 claims 1
- 101100226845 Strongylocentrotus purpuratus EGF2 gene Proteins 0.000 claims 1
- 102220536512 THAP domain-containing protein 1_S52A_mutation Human genes 0.000 claims 1
- 102220521977 THAP domain-containing protein 1_T28A_mutation Human genes 0.000 claims 1
- 102220504159 Testis-specific XK-related protein, Y-linked 2_N93Q_mutation Human genes 0.000 claims 1
- 102220524532 Tumor necrosis factor receptor superfamily member 19_S31T_mutation Human genes 0.000 claims 1
- 206010046798 Uterine leiomyoma Diseases 0.000 claims 1
- 102220594970 Vasopressin-neurophysin 2-copeptin_T51N_mutation Human genes 0.000 claims 1
- 102220514520 Vitronectin_T76E_mutation Human genes 0.000 claims 1
- 102220559219 Voltage-dependent L-type calcium channel subunit alpha-1C_S30R_mutation Human genes 0.000 claims 1
- 102220469732 Voltage-dependent L-type calcium channel subunit beta-2_S53A_mutation Human genes 0.000 claims 1
- 102220532167 WW domain-binding protein 11_D50S_mutation Human genes 0.000 claims 1
- 239000000443 aerosol Substances 0.000 claims 1
- 239000000556 agonist Substances 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 102200016928 c.100G>A Human genes 0.000 claims 1
- 102220437982 c.160G>T Human genes 0.000 claims 1
- 102220353096 c.163G>C Human genes 0.000 claims 1
- 102220290142 c.186C>A Human genes 0.000 claims 1
- 102220349282 c.275C>G Human genes 0.000 claims 1
- 102220358598 c.296C>G Human genes 0.000 claims 1
- 102200107976 c.296C>T Human genes 0.000 claims 1
- 102220346421 c.92C>A Human genes 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 239000006071 cream Substances 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 238000012217 deletion Methods 0.000 claims 1
- 230000037430 deletion Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 210000002889 endothelial cell Anatomy 0.000 claims 1
- 239000000499 gel Substances 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 238000003780 insertion Methods 0.000 claims 1
- 230000037431 insertion Effects 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 201000010260 leiomyoma Diseases 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 239000002674 ointment Substances 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 239000006072 paste Substances 0.000 claims 1
- 239000006187 pill Substances 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 201000011461 pre-eclampsia Diseases 0.000 claims 1
- 230000002062 proliferating effect Effects 0.000 claims 1
- 206010038038 rectal cancer Diseases 0.000 claims 1
- 201000001275 rectum cancer Diseases 0.000 claims 1
- 230000001850 reproductive effect Effects 0.000 claims 1
- 102200103823 rs104886043 Human genes 0.000 claims 1
- 102200046706 rs104893869 Human genes 0.000 claims 1
- 102200046707 rs104893869 Human genes 0.000 claims 1
- 102200076230 rs104894127 Human genes 0.000 claims 1
- 102200142367 rs104894554 Human genes 0.000 claims 1
- 102220196624 rs1057518977 Human genes 0.000 claims 1
- 102220218621 rs1060501106 Human genes 0.000 claims 1
- 102220233028 rs1085307691 Human genes 0.000 claims 1
- 102220028823 rs115928999 Human genes 0.000 claims 1
- 102200148733 rs116840794 Human genes 0.000 claims 1
- 102200118914 rs120074145 Human genes 0.000 claims 1
- 102200058924 rs121909542 Human genes 0.000 claims 1
- 102200115358 rs121918322 Human genes 0.000 claims 1
- 102220036452 rs137882485 Human genes 0.000 claims 1
- 102220191772 rs149875299 Human genes 0.000 claims 1
- 102220318984 rs150326789 Human genes 0.000 claims 1
- 102200061168 rs150338273 Human genes 0.000 claims 1
- 102220242992 rs1553178041 Human genes 0.000 claims 1
- 102220317885 rs1554069716 Human genes 0.000 claims 1
- 102220320206 rs1554431444 Human genes 0.000 claims 1
- 102220287941 rs1555932714 Human genes 0.000 claims 1
- 102200048328 rs1801270 Human genes 0.000 claims 1
- 102200133063 rs199473350 Human genes 0.000 claims 1
- 102220008235 rs199476326 Human genes 0.000 claims 1
- 102200082871 rs35802118 Human genes 0.000 claims 1
- 102220084157 rs370502517 Human genes 0.000 claims 1
- 102220240604 rs373669452 Human genes 0.000 claims 1
- 102200050844 rs386833793 Human genes 0.000 claims 1
- 102220016203 rs397507622 Human genes 0.000 claims 1
- 102220020162 rs397508045 Human genes 0.000 claims 1
- 102220139130 rs570799464 Human genes 0.000 claims 1
- 102220041238 rs587778670 Human genes 0.000 claims 1
- 102200114146 rs61748123 Human genes 0.000 claims 1
- 102200001738 rs72552724 Human genes 0.000 claims 1
- 102200123491 rs72555390 Human genes 0.000 claims 1
- 102220058298 rs730881402 Human genes 0.000 claims 1
- 102220218616 rs746322193 Human genes 0.000 claims 1
- 102220082204 rs753215899 Human genes 0.000 claims 1
- 102220315596 rs762200707 Human genes 0.000 claims 1
- 102220121884 rs768260007 Human genes 0.000 claims 1
- 102220092171 rs770694213 Human genes 0.000 claims 1
- 102220463950 rs7782939 Human genes 0.000 claims 1
- 102220328494 rs78028658 Human genes 0.000 claims 1
- 102220097978 rs780920036 Human genes 0.000 claims 1
- 102220328195 rs781611267 Human genes 0.000 claims 1
- 102220062178 rs786202417 Human genes 0.000 claims 1
- 102220087056 rs864622464 Human genes 0.000 claims 1
- 102220172123 rs886048669 Human genes 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 239000000829 suppository Substances 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
- 210000001215 vagina Anatomy 0.000 claims 1
- 210000003905 vulva Anatomy 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US19876408P | 2008-11-07 | 2008-11-07 | |
| US61/198,764 | 2008-11-07 | ||
| US21120409P | 2009-03-25 | 2009-03-25 | |
| US61/211,204 | 2009-03-25 | ||
| PCT/US2009/063303 WO2010054010A1 (en) | 2008-11-07 | 2009-11-04 | Anti-dll4 antibodies and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015157842A Division JP2016040246A (ja) | 2008-11-07 | 2015-08-10 | 抗ｄｌｌ４抗体及びその使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012508017A JP2012508017A (ja) | 2012-04-05 |
| JP2012508017A5 true JP2012508017A5 (OSRAM) | 2013-01-24 |
Family
ID=41508157
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011535649A Expired - Fee Related JP5882058B2 (ja) | 2008-11-07 | 2009-11-04 | 組合せ抗体ライブラリー及びその使用 |
| JP2011535651A Pending JP2012508017A (ja) | 2008-11-07 | 2009-11-04 | 抗ｄｌｌ４抗体及びその使用 |
| JP2015157842A Pending JP2016040246A (ja) | 2008-11-07 | 2015-08-10 | 抗ｄｌｌ４抗体及びその使用 |
| JP2016018531A Pending JP2016127850A (ja) | 2008-11-07 | 2016-02-03 | 組合せ抗体ライブラリー及びその使用 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011535649A Expired - Fee Related JP5882058B2 (ja) | 2008-11-07 | 2009-11-04 | 組合せ抗体ライブラリー及びその使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015157842A Pending JP2016040246A (ja) | 2008-11-07 | 2015-08-10 | 抗ｄｌｌ４抗体及びその使用 |
| JP2016018531A Pending JP2016127850A (ja) | 2008-11-07 | 2016-02-03 | 組合せ抗体ライブラリー及びその使用 |
Country Status (7)
| Country | Link |
|---|---|
| US (4) | US9403904B2 (OSRAM) |
| EP (2) | EP2356270B1 (OSRAM) |
| JP (4) | JP5882058B2 (OSRAM) |
| AU (4) | AU2009313560B2 (OSRAM) |
| CA (2) | CA2742968C (OSRAM) |
| DK (1) | DK2356270T3 (OSRAM) |
| WO (2) | WO2010054010A1 (OSRAM) |
Families Citing this family (205)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011053822A2 (en) * | 2009-11-01 | 2011-05-05 | The Brigham And Women's Hospital, Inc. | Notch inhibition in the treatment and prevention of obesity and metabolic syndrome |
| US9567396B2 (en) | 2006-03-07 | 2017-02-14 | Evonik Degussa Gmbh | Notch inhibition in the prevention of vein graft failure |
| EA018260B1 (ru) | 2006-09-29 | 2013-06-28 | Онкомед Фармасьютикалз, Инк. | Антитела к дельта-подобному лиганду 4 человека и их применение |
| EP2738257A1 (en) | 2007-05-22 | 2014-06-04 | Amgen Inc. | Compositions and methods for producing bioactive fusion proteins |
| EP2993186B1 (en) | 2008-03-14 | 2019-09-04 | Biocon Limited | A monoclonal antibody and a method thereof |
| CA2742968C (en) | 2008-11-07 | 2020-06-09 | Fabrus Llc | Combinatorial antibody libraries and uses thereof |
| CA2755133A1 (en) | 2009-03-20 | 2010-09-23 | Amgen Inc. | Selective and potent peptide inhibitors of kv1.3 |
| WO2010121370A1 (en) * | 2009-04-20 | 2010-10-28 | University Health Network | Prognostic gene expression signature for squamous cell carcinoma of the lung |
| ES2511051T3 (es) | 2009-05-29 | 2014-10-22 | Morphosys Ag | Colección de anticuerpos sintéticos para tratar enfermedades |
| TWI513465B (zh) * | 2009-06-25 | 2015-12-21 | Regeneron Pharma | 以ｄｌｌ４拮抗劑與化學治療劑治療癌症之方法 |
| PL2488204T3 (pl) | 2009-10-16 | 2016-10-31 | Kombinacja terapeutyczna i zastosowanie przeciwciał antagonistycznych względem dll4 i środków antyhipertensyjnych | |
| CA2780221A1 (en) | 2009-11-04 | 2011-05-12 | Fabrus Llc | Methods for affinity maturation-based antibody optimization |
| UA109888C2 (uk) | 2009-12-07 | 2015-10-26 | ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ | |
| US10016620B2 (en) | 2010-02-04 | 2018-07-10 | Procept Biorobotics Incorporation | Tissue sampling and cancer treatment apparatus |
| US20130045492A1 (en) | 2010-02-08 | 2013-02-21 | Regeneron Pharmaceuticals, Inc. | Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain |
| US20120021409A1 (en) * | 2010-02-08 | 2012-01-26 | Regeneron Pharmaceuticals, Inc. | Common Light Chain Mouse |
| US9796788B2 (en) | 2010-02-08 | 2017-10-24 | Regeneron Pharmaceuticals, Inc. | Mice expressing a limited immunoglobulin light chain repertoire |
| ES2547142T5 (es) | 2010-02-08 | 2021-12-09 | Regeneron Pharma | Cadena ligera común de ratón |
| EP3336225B1 (en) | 2010-07-16 | 2020-02-19 | Adimab, LLC | Antibody libraries |
| CN103168104B (zh) | 2010-07-22 | 2016-09-28 | 加利福尼亚大学董事会 | 抗肿瘤抗原抗体及其使用方法 |
| US8551479B2 (en) | 2010-09-10 | 2013-10-08 | Oncomed Pharmaceuticals, Inc. | Methods for treating melanoma |
| EP2725034B1 (en) | 2010-09-22 | 2019-04-03 | Amgen Inc. | Carrier immunoglobulins with no specificity for human tissues and uses thereof |
| WO2012066129A1 (en) | 2010-11-19 | 2012-05-24 | Morphosys Ag | A collection and methods for its use |
| US20160272697A2 (en) * | 2011-04-28 | 2016-09-22 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | Neutralizing Antibodies to Nipah and Hendra Virus |
| SG194233A1 (en) * | 2011-04-28 | 2013-12-30 | Univ Leland Stanford Junior | Identification of polynucleotides associated with a sample |
| EP3725811A3 (en) | 2011-05-04 | 2021-01-27 | Omeros Corporation | Compositions for inhibiting masp-2 dependent complement activation |
| WO2012171996A1 (en) | 2011-06-15 | 2012-12-20 | F. Hoffmann-La Roche Ag | Anti-human epo receptor antibodies and methods of use |
| IL273982B2 (en) | 2011-08-05 | 2023-03-01 | Regeneron Pharma | Humanized mice possess a universal light chain |
| ES2682254T3 (es) * | 2011-08-18 | 2018-09-19 | Affinity Biosciences Pty Ltd | Polipéptidos solubles |
| DK3485903T5 (da) | 2011-09-23 | 2024-09-02 | Mereo Biopharma 5 Inc | Vegf/dll4-bindende midler og anvendelser deraf |
| CN104053671A (zh) | 2011-11-01 | 2014-09-17 | 生态学有限公司 | 治疗癌症的抗体和方法 |
| AU2012332588B2 (en) | 2011-11-01 | 2017-09-07 | Bionomics, Inc. | Methods of blocking cancer stem cell growth |
| US10774132B2 (en) | 2012-01-09 | 2020-09-15 | The Scripps Research Instittue | Ultralong complementarity determining regions and uses thereof |
| US20150011431A1 (en) | 2012-01-09 | 2015-01-08 | The Scripps Research Institute | Humanized antibodies |
| IN2014CN04645A (OSRAM) * | 2012-01-31 | 2015-09-18 | Regeneron Pharma | |
| WO2013131074A1 (en) * | 2012-03-02 | 2013-09-06 | Diogenix, Inc. | Methods and reagents for evaluating autoimmune disease and determining antibody repertoire |
| CN104379602B (zh) | 2012-03-08 | 2017-05-03 | 哈洛齐梅公司 | 具有条件活性的抗表皮生长因子受体抗体及其使用方法 |
| CN104994872B (zh) * | 2012-06-21 | 2018-09-14 | 索伦托治疗有限公司 | 与igf1r结合的抗原结合蛋白 |
| KR101535341B1 (ko) * | 2012-07-02 | 2015-07-13 | 한화케미칼 주식회사 | Dll4에 특이적으로 결합하는 신규한 단일클론항체 및 이의 용도 |
| WO2014052713A2 (en) | 2012-09-27 | 2014-04-03 | Massachusetts Institute Of Technology | Her2-and vegf-a-binding proteins with enhanced stability |
| US9309318B2 (en) * | 2012-10-17 | 2016-04-12 | Amgen, Inc. | Compositions relating to anti-IL-21 receptor antibodies |
| AU2013337811A1 (en) * | 2012-10-31 | 2015-05-14 | Oncomed Pharmaceuticals, Inc. | Methods and monitoring of treatment with a DLL4 antagonist |
| BR112015010240A2 (pt) * | 2012-11-06 | 2017-08-22 | Medimmune Ltd | Terapias de combinação através do uso de mo-léculas de ligação de psl e de pcrv anti-pseudomonas |
| US10407503B2 (en) * | 2012-11-30 | 2019-09-10 | The Regents Of The University Of California | Fully human antibodies and fragments recognizing human c-Met |
| EP3851454A1 (en) | 2012-12-05 | 2021-07-21 | Novartis AG | Compositions and methods for antibodies targeting epo |
| RU2639505C2 (ru) | 2013-01-24 | 2017-12-21 | ЭбТЛАС КО., Лтд. | Библиотека fv на основе комбинаций белков и способ ее получения |
| US9896685B2 (en) | 2013-04-25 | 2018-02-20 | Sutro Biopharma, Inc. | Use of LAMBDA-GAM protein in ribosomal display technology |
| EP2989239B2 (en) * | 2013-04-25 | 2025-01-15 | Sutro Biopharma, Inc. | Selection of fab fragments using ribosomal display technology |
| RU2539752C2 (ru) * | 2013-05-23 | 2015-01-27 | Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) | ГУМАНИЗИРОВАННОЕ АНТИТЕЛО И АНТИГЕНСВЯЗЫВАЮЩИЙ ФРАГМЕНТ (Fab), СВЯЗЫВАЮЩИЕСЯ С ИНТЕРФЕРОНОМ- γ ЧЕЛОВЕКА, ФРАГМЕНТЫ ДНК, КОДИРУЮЩИЕ УКАЗАННОЕ АНТИТЕЛО И АНТИГЕНСВЯЗЫВАЮЩИЙ ФРАГМЕНТ, КЛЕТКА, ТРАНСФОРМИРОВАННАЯ ФРАГМЕНТОМ ДНК, И СПОСОБ ПОЛУЧЕНИЯ УКАЗАННОГО АНТИТЕЛА И АНТИГЕНСВЯЗЫВАЮЩЕГО ФРАГМЕНТА |
| US10208125B2 (en) | 2013-07-15 | 2019-02-19 | University of Pittsburgh—of the Commonwealth System of Higher Education | Anti-mucin 1 binding agents and uses thereof |
| CN111518199A (zh) | 2013-07-18 | 2020-08-11 | 图鲁斯生物科学有限责任公司 | 具有超长互补决定区的人源化抗体 |
| US20160168231A1 (en) | 2013-07-18 | 2016-06-16 | Fabrus, Inc. | Antibodies with ultralong complementarity determining regions |
| CN113667013B (zh) * | 2013-10-02 | 2024-04-09 | 免疫医疗有限责任公司 | 中和抗甲型流感抗体及其用途 |
| WO2015057906A1 (en) * | 2013-10-16 | 2015-04-23 | Janssen Biotech, Inc. | Cd200 receptor 1 agonists |
| GB201403775D0 (en) * | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
| MX2016011637A (es) | 2014-03-14 | 2017-04-13 | Genentech Inc | Metodos y composiciones para secrecion de polipeptidos heterologos. |
| BR112016021572A2 (pt) | 2014-03-21 | 2017-10-03 | Regeneron Pharma | Métodos para preparar um animal não humano geneticamente modificado e para produzir proteínas de ligação, hibridoma, ácido nucleico, célula, e, proteína de ligação |
| WO2015153912A1 (en) | 2014-04-03 | 2015-10-08 | Igm Biosciences, Inc. | Modified j-chain |
| US9546214B2 (en) | 2014-04-04 | 2017-01-17 | Bionomics, Inc. | Humanized antibodies that bind LGR5 |
| GB201407852D0 (en) | 2014-05-02 | 2014-06-18 | Iontas Ltd | Preparation of libraries od protein variants expressed in eukaryotic cells and use for selecting binding molecules |
| ES2886204T3 (es) * | 2014-06-24 | 2021-12-16 | Procept Biorobotics Corp | Aparato de muestreo de tejidos y tratamiento del cáncer |
| CA2954780A1 (en) | 2014-07-15 | 2016-01-21 | Medimmune, Llc | Neutralizing anti-influenza b antibodies and uses thereof |
| AU2015308625A1 (en) * | 2014-08-29 | 2017-04-20 | Sorrento Therapeutics, Inc. | Antibody therapeutics that bind OprF and Oprl |
| CN107405397B (zh) | 2014-10-27 | 2020-08-25 | 新加坡科技研究局 | 抗tim-3抗体 |
| GB201419094D0 (en) | 2014-10-27 | 2014-12-10 | Agency Science Tech & Res | Anti-TIM-3-antibodies |
| JP6827415B2 (ja) | 2014-10-31 | 2021-02-10 | メレオ バイオファーマ ５ インコーポレイテッド | 疾患の処置のための併用療法 |
| CN108064244B (zh) | 2014-11-14 | 2021-09-17 | 诺华股份有限公司 | 抗体药物缀合物 |
| EP3026060A1 (en) * | 2014-11-26 | 2016-06-01 | Miltenyi Biotec GmbH | Humanized antibody or fragment thereof specific for CD45R0 |
| ES2966099T3 (es) | 2014-12-05 | 2024-04-18 | Memorial Sloan Kettering Cancer Center | Receptores de antígeno quiméricos dirigidos al antígeno de maduración de células B y usos de los mismos |
| HUE053995T2 (hu) | 2014-12-05 | 2021-08-30 | Memorial Sloan Kettering Cancer Center | B-sejt-érési antigént célzó antitestek és alkalmazási eljárások |
| EP3246434A1 (en) * | 2015-01-13 | 2017-11-22 | Ewha University-Industry Collaboration Foundation | Method for preparing novel antibody library and library prepared thereby |
| US10100126B2 (en) * | 2015-03-10 | 2018-10-16 | Sorrento Therapeutics, Inc. | Antibody therapeutics that bind PSMA |
| EP3271403A1 (en) | 2015-03-19 | 2018-01-24 | Regeneron Pharmaceuticals, Inc. | Non-human animals that select for light chain variable regions that bind antigen |
| EP4180058A1 (en) | 2015-04-08 | 2023-05-17 | Sorrento Therapeutics, Inc. | Antibody therapeutics that bind cd38 |
| AR104309A1 (es) | 2015-04-17 | 2017-07-12 | Bayer Pharma AG | Construcciones de anticuerpos biespecíficos para cdh3 y cd3 |
| TWI716405B (zh) | 2015-05-07 | 2021-01-21 | 美商艾吉納斯公司 | 抗ox40抗體及其使用方法 |
| JP6913030B2 (ja) | 2015-05-18 | 2021-08-04 | アジェンシス，インコーポレイテッド | Ａｘｌタンパク質に結合する抗体 |
| WO2016187354A1 (en) | 2015-05-18 | 2016-11-24 | Agensys, Inc. | Antibodies that bind to axl proteins |
| HUE056407T2 (hu) | 2015-06-01 | 2022-02-28 | Medimmune Llc | Neutralizáló influenzaellenes kötõmolekulák és alkalmazásaik |
| US20180155411A1 (en) * | 2015-07-08 | 2018-06-07 | The Board Of Trustees Of The Leland Stanford Junior University | Heterotypic antibodies specific for human rotavirus |
| ES2913530T3 (es) | 2015-08-12 | 2022-06-02 | Novartis Ag | Métodos para tratar trastornos oftálmicos |
| ES2968074T3 (es) | 2015-09-23 | 2024-05-07 | Mereo Biopharma 5 Inc | Anticuerpo bi-específico anti-VEGF/DLL4 para su uso en el tratamiento del cáncer de ovario resistente al platino |
| HK1252791A1 (zh) | 2015-09-30 | 2019-06-06 | Igm Biosciences, Inc. | 具有经修饰的j链的结合分子 |
| DK3356401T3 (da) | 2015-09-30 | 2020-09-07 | Igm Biosciences Inc | Bindingsmolekyler med modificeret j-kæde |
| TWI752920B (zh) | 2015-10-12 | 2022-01-21 | 美商再生元醫藥公司 | 活化瘦素受體的抗原結合蛋白 |
| EP3184547A1 (en) * | 2015-10-29 | 2017-06-28 | F. Hoffmann-La Roche AG | Anti-tpbg antibodies and methods of use |
| PT3374398T (pt) | 2015-11-10 | 2020-06-16 | Medimmune Llc | Moléculas de ligação específicas para asct2 e suas utilizações |
| EP3383430A4 (en) | 2015-12-02 | 2019-12-18 | Agenus Inc. | ANTIBODIES AND METHOD FOR USE THEREOF |
| MA43389A (fr) * | 2015-12-02 | 2021-05-12 | Agenus Inc | Anticorps anti-ox40 et leurs procédés d'utilisation |
| WO2017096182A1 (en) * | 2015-12-03 | 2017-06-08 | Agenus Inc. | Anti-ox40 antibodies and methods of use thereof |
| CN106939047B (zh) | 2016-01-04 | 2021-08-31 | 江苏怀瑜药业有限公司 | 一种pd-l1抗体及其制备方法 |
| CN105693821A (zh) * | 2016-01-08 | 2016-06-22 | 中国药科大学 | 与人血管内皮生长因子受体-3(vegfr-3)蛋白特异性结合的多肽，其筛选方法，鉴定和用途 |
| CN108699150B (zh) * | 2016-01-08 | 2022-08-09 | 科凌生物医疗有限公司 | 治疗性抗-cd9抗体 |
| US20190015509A1 (en) | 2016-01-13 | 2019-01-17 | Medimmune, Llc | Method of treating influenza a |
| WO2017124001A2 (en) * | 2016-01-14 | 2017-07-20 | Memorial Sloan-Kettering Cancer Center | T cell receptor-like antibodies specific for foxp3-derived peptides |
| EP3432925A4 (en) | 2016-03-22 | 2019-11-06 | Bionomics Limited | ADMINISTRATION OF A MONOCLONAL ANTI-LGR5 ANTIBODY |
| WO2017180936A1 (en) * | 2016-04-15 | 2017-10-19 | The Trustees Of The University Of Pennsylvania | Compositions for treatment of wet age-related macular degeneration |
| EA201892716A1 (ru) * | 2016-06-14 | 2019-05-31 | Мерк Шарп И Доум Корп. | Антитела к фактору свертывания xi |
| JP7461741B2 (ja) | 2016-06-20 | 2024-04-04 | カイマブ・リミテッド | 抗ｐｄ－ｌ１およびｉｌ－２サイトカイン |
| MA45491A (fr) | 2016-06-27 | 2019-05-01 | Juno Therapeutics Inc | Épitopes à restriction cmh-e, molécules de liaison et procédés et utilisations associés |
| EP3475446A1 (en) | 2016-06-27 | 2019-05-01 | Juno Therapeutics, Inc. | Method of identifying peptide epitopes, molecules that bind such epitopes and related uses |
| US11168148B2 (en) | 2016-09-07 | 2021-11-09 | The Regents Of The University Of California | Antibodies to oxidation-specific epitopes |
| EP3515936A1 (en) * | 2016-09-23 | 2019-07-31 | Elstar Therapeutics, Inc. | Multispecific antibody molecules comprising lambda and kappa light chains |
| US10738338B2 (en) | 2016-10-18 | 2020-08-11 | The Research Foundation for the State University | Method and composition for biocatalytic protein-oligonucleotide conjugation and protein-oligonucleotide conjugate |
| WO2018075621A1 (en) * | 2016-10-19 | 2018-04-26 | Vanderbilt University | Human orthopoxvirus antibodies and methods of use therefor |
| WO2018081755A1 (en) * | 2016-10-29 | 2018-05-03 | University Of Miami | Zika virus antibodies |
| EP3534947A1 (en) | 2016-11-03 | 2019-09-11 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses & methods |
| FI3538554T3 (fi) | 2016-11-08 | 2025-09-24 | Regeneron Pharma | Antigeeniä sitovia proteiineja, jotka antagonisoivat leptiinireseptoria |
| WO2018089628A1 (en) * | 2016-11-09 | 2018-05-17 | Agenus Inc. | Anti-ox40 antibodies, anti-gitr antibodies, and methods of use thereof |
| KR20190083654A (ko) * | 2016-11-10 | 2019-07-12 | 메디뮨 엘엘씨 | Asct2에 특이적인 결합 분자 및 이의 용도 |
| BR112019011186A2 (pt) | 2016-12-01 | 2019-10-08 | Regeneron Pharmaceuticals, Inc. | conjugado de anticorpo radiomarcado, composto, e, métodos de imageamento e para tratamento de um tumor. |
| RS65187B1 (sr) * | 2016-12-19 | 2024-03-29 | Medimmune Ltd | Antitela na lif i njihove primene |
| IL268554B2 (en) | 2017-02-08 | 2025-03-01 | Dragonfly Therapeutics Inc | Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer |
| WO2018151836A1 (en) | 2017-02-17 | 2018-08-23 | Fred Hutchinson Cancer Research Center | Combination therapies for treatment of bcma-related cancers and autoimmune disorders |
| CN108456250B (zh) * | 2017-02-17 | 2025-11-28 | 恺兴生命科技(上海)有限公司 | 靶向il-13ra2的抗体及其应用 |
| CA3235295C (en) | 2017-02-20 | 2024-11-19 | Dragonfly Therapeutics, Inc. | Proteins binding her2, nkg2d and cd16 |
| US11161905B2 (en) * | 2017-03-04 | 2021-11-02 | Xiangtan Tenghua Bioscience | Recombinant antibodies to programmed death 1 (PD-1) and uses thereof |
| JOP20180021A1 (ar) * | 2017-03-16 | 2019-01-30 | Janssen Biotech Inc | الأجسام المضادة لتكتلات خيوط بروتين تاو (tau) الحلزونية المزدوجة واستخداماتها |
| US11879014B2 (en) | 2017-03-17 | 2024-01-23 | Tusk Therapeutics Ltd. | Method of treating cancer or depleting regulatory T cells in a subject by administering a human IGG1 anti-CD25 antibody |
| US10296425B2 (en) | 2017-04-20 | 2019-05-21 | Bank Of America Corporation | Optimizing data processing across server clusters and data centers using checkpoint-based data replication |
| US11976121B2 (en) | 2017-07-20 | 2024-05-07 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | CD123-binding chimeric antigen receptors |
| JP7113071B2 (ja) * | 2017-07-31 | 2022-08-04 | トリシュラ セラピューティクス， インコーポレイテッド | 抗ｃｄ３９抗体、抗ｃｄ３９抗体を含む組成物、および抗ｃｄ３９抗体を使用する方法 |
| US20210147550A1 (en) * | 2017-08-18 | 2021-05-20 | Joshua Michael Francis | Antigen-binding proteins targeting shared antigens |
| WO2019089969A2 (en) | 2017-11-01 | 2019-05-09 | Juno Therapeutics, Inc. | Antibodies and chimeric antigen receptors specific for b-cell maturation antigen |
| WO2019090003A1 (en) | 2017-11-01 | 2019-05-09 | Juno Therapeutics, Inc. | Chimeric antigen receptors specific for b-cell maturation antigen (bcma) |
| SG11202003427XA (en) | 2017-11-06 | 2020-05-28 | Juno Therapeutics Inc | Combination of a cell therapy and a gamma secretase inhibitor |
| EP3713964B1 (en) | 2017-11-20 | 2024-01-17 | NantBio, Inc. | An mrna display antibody library and methods |
| US11034951B2 (en) | 2017-11-20 | 2021-06-15 | Nantbio, Inc. | mRNA display antibody library and methods |
| AU2018390811A1 (en) | 2017-12-18 | 2020-07-02 | Regeneron Pharmaceuticals, Inc. | Bispecific antigen binding molecules that bind leptin receptor and/or GP130, and methods of use thereof |
| US11746150B2 (en) | 2017-12-19 | 2023-09-05 | Surrozen Operating, Inc. | Anti-LRP5/6 antibodies and methods of use |
| JP7418332B2 (ja) | 2017-12-19 | 2024-01-19 | スロゼン オペレーティング， インコーポレイテッド | 抗フリズルド抗体及び使用方法 |
| CN118271444A (zh) | 2017-12-19 | 2024-07-02 | 瑟罗泽恩奥普瑞汀公司 | Wnt替代分子和其用途 |
| WO2019143884A1 (en) * | 2018-01-19 | 2019-07-25 | Vanderbilt University | Conserved hiv antibody clonotypes and methods of use |
| US12384847B2 (en) | 2018-02-08 | 2025-08-12 | Dragonfly Therapeutics, Inc. | Cancer therapy involving an anti-PD1 antibody and a multi-specific binding protein that binds NKG2D, CD16, and a tumor-associated antigen |
| US11884733B2 (en) | 2018-02-08 | 2024-01-30 | Dragonfly Therapeutics, Inc. | Antibody variable domains targeting the NKG2D receptor |
| US12215157B2 (en) | 2018-02-20 | 2025-02-04 | Dragonfly Therapeutics, Inc. | Multi-specific binding proteins that bind CD33, NKG2D, and CD16, and methods of use |
| EA202092088A1 (ru) | 2018-03-05 | 2020-11-13 | Янссен Фармацевтика Нв | Антитела анти-phf-тау и их применение |
| SG11202008733YA (en) | 2018-03-13 | 2020-10-29 | Tusk Therapeutics Ltd | Anti-cd25 for tumour specific cell depletion |
| CA3094400A1 (en) | 2018-04-06 | 2019-10-10 | Regeneron Pharmaceuticals, Inc. | A leptin receptor agonist antibody for use in treating a metabolic dysfunction or hypoleptinemia |
| EP3553079A1 (en) * | 2018-04-12 | 2019-10-16 | Bayer Aktiengesellschaft | C-type natriuretic peptide engrafted antibodies |
| EP3553081A1 (en) * | 2018-04-12 | 2019-10-16 | Bayer Aktiengesellschaft | Atrial natriuretic peptide engrafted antibodies |
| EP3553082A1 (en) | 2018-04-12 | 2019-10-16 | Bayer Aktiengesellschaft | Brain natriuretic peptide engrafted antibodies |
| US12036242B2 (en) | 2018-07-05 | 2024-07-16 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | CAR T cells that target B-cell antigens |
| JP7332691B2 (ja) | 2018-07-08 | 2023-08-23 | スペシフィカ インコーポレイティド | 抗体の開発可能性が最大化された抗体ライブラリー |
| CN110713537B (zh) * | 2018-07-13 | 2023-04-21 | 江苏怀瑜药业有限公司 | 一种sema4d抗体及其制备方法和应用 |
| MA53284A (fr) | 2018-08-08 | 2022-01-26 | Dragonfly Therapeutics Inc | Protéines de liaison à nkg2d, à cd16 et à un antigène associé à une tumeur |
| EA202091888A1 (ru) | 2018-08-08 | 2020-10-23 | Драгонфлай Терапьютикс, Инк. | Вариабельные домены антител, нацеленные на рецептор nkg2d |
| EP3833392A4 (en) | 2018-08-08 | 2022-05-18 | Dragonfly Therapeutics, Inc. | Multi-specific binding proteins that bind bcma, nkg2d and cd16, and methods of use |
| BR112021003830A2 (pt) | 2018-08-28 | 2021-07-20 | Fred Hutchinson Cancer Research Center | métodos e composições para terapia celular t adotiva incorporando sinalização notch induzida |
| KR20210113169A (ko) | 2018-11-01 | 2021-09-15 | 주노 쎄러퓨티크스 인코퍼레이티드 | Β세포 성숙 항원에 특이적인 키메라 항원 수용체를 이용한 치료 방법 |
| CN109553680B (zh) * | 2018-12-12 | 2021-06-01 | 广州市第八人民医院 | 一种单克隆抗体ZKns4B8及其应用 |
| KR20210108961A (ko) * | 2018-12-28 | 2021-09-03 | 쿄와 기린 가부시키가이샤 | TfR에 결합하는 이중 특이적 항체 |
| KR20240166044A (ko) * | 2019-01-31 | 2024-11-25 | 난트바이오 인코포레이티드 | Mrna 디스플레이 항체 라이브러리 및 방법 |
| CN118546959A (zh) | 2019-03-05 | 2024-08-27 | 恩卡尔塔公司 | Cd19定向性嵌合抗原受体及其在免疫疗法中的用途 |
| US12479908B2 (en) | 2019-03-29 | 2025-11-25 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Antibodies against programmed cell death protein 1 (PD1) and uses thereof |
| JP2022530442A (ja) * | 2019-04-24 | 2022-06-29 | マジェンタ セラピューティクス インコーポレイテッド | アントラサイクリン抗体薬物複合体およびその使用 |
| US20220396631A1 (en) * | 2019-05-21 | 2022-12-15 | Lu HUANG | Trispecific binding molecules against bcma and uses thereof |
| WO2020247883A2 (en) * | 2019-06-07 | 2020-12-10 | Scribe Therapeutics Inc. | Deep mutational evolution of biomolecules |
| WO2020247882A1 (en) | 2019-06-07 | 2020-12-10 | Scribe Therapeutics Inc. | Engineered casx systems |
| US12448462B2 (en) | 2019-06-14 | 2025-10-21 | Dana-Farber Cancer Institute, Inc. | Antibodies against MUC1 |
| AU2020300618A1 (en) * | 2019-07-02 | 2022-01-27 | Surrozen Operating, Inc. | Monospecific anti-frizzled antibodies and methods of use |
| JP7685985B2 (ja) * | 2019-07-16 | 2025-05-30 | サノフイ | アルツハイマー病の処置のための中和抗アミロイドベータ抗体 |
| EP4034564A4 (en) * | 2019-09-23 | 2023-12-13 | Twist Bioscience Corporation | VARIANT NUCLEIC ACID LIBRARIES FOR SINGLE-DOMAIN ANTIBODIES |
| US12091777B2 (en) | 2019-09-23 | 2024-09-17 | Twist Bioscience Corporation | Variant nucleic acid libraries for CRTH2 |
| MX2022004942A (es) * | 2019-10-24 | 2022-07-27 | Prometheus Biosciences Inc | Anticuerpos humanizados contra el ligando 1a de tipo tnf (tl1a) y usos de los mismos. |
| CN115443140A (zh) * | 2020-04-02 | 2022-12-06 | 苏州恒康生命科学有限公司 | 人ror-1抗体和抗ror-1-car-t细胞 |
| EP4142784A4 (en) * | 2020-04-27 | 2024-12-18 | Twist Bioscience Corporation | VARIANT NUCLEIC ACID BANKS FOR CORONAVIRUS |
| TW202208428A (zh) | 2020-05-06 | 2022-03-01 | 美商蜻蜓醫療公司 | 結合ｎｋｇ２ｄ、ｃｄ１６及ｃｌｅｃ１２ａ之蛋白質 |
| EP4153625A4 (en) * | 2020-05-20 | 2024-09-25 | The Trustees Of Columbia University In The City Of New York | STRONG NEUTRALISING ANTIBODIES AGAINST SARS-COV-2, THEIR PRODUCTION AND USE |
| CN111748033B (zh) * | 2020-05-27 | 2021-02-02 | 江苏省疾病预防控制中心(江苏省公共卫生研究院) | 一种与新型冠状病毒np蛋白结合的分离抗体、包含其的检测试剂盒 |
| IL298510A (en) | 2020-06-12 | 2023-01-01 | Nkarta Inc | Genetically modified natural killer cells for cd70-directed cancer immunotherapy |
| EP4154910A4 (en) * | 2020-06-30 | 2024-09-11 | Harbour Biomed (Shanghai) Co., Ltd | Binding protein having h2l2 and hcab structures |
| US20230348902A1 (en) * | 2020-08-10 | 2023-11-02 | Integral Molecular, Inc. | Methods and compositions for making antibody libraries and antibodies isolated from the same |
| US20230391856A1 (en) * | 2020-10-23 | 2023-12-07 | Icahn School Of Medicine At Mount Sinai | Sars-cov-2 antibodies and uses thereof |
| EP4256054A1 (en) | 2020-12-03 | 2023-10-11 | Scribe Therapeutics Inc. | Engineered class 2 type v crispr systems |
| AU2021392748A1 (en) * | 2020-12-04 | 2023-06-29 | Equillium, Inc. | Methods of selectively targeting cd6 high cells and decreasing activity of t eff cells |
| US20240228588A1 (en) * | 2021-01-11 | 2024-07-11 | Adimab, Llc | Variant ch1 domains and variant cl domains engineered for preferential chain pairing and multi-specific antibodies comprising the same |
| EP4301774A4 (en) | 2021-03-03 | 2025-08-13 | Dragonfly Therapeutics Inc | METHODS OF TREATING CANCER USING MULTI-SPECIFIC BINDING PROTEINS THAT BIND TO NKG2D, CD16, AND A TUMOR-ASSOCIATED ANTIGEN |
| WO2022192661A1 (en) * | 2021-03-12 | 2022-09-15 | Board Of Regents, The University Of Texas System | Sars-cov-2 neutralizing antibodies and uses thereof |
| US12258406B2 (en) | 2021-03-24 | 2025-03-25 | Twist Bioscience Corporation | Antibodies that bind CD3 Epsilon |
| CN117940450A (zh) | 2021-06-17 | 2024-04-26 | 阿萃卡公司 | 抗csp抗体 |
| KR20240033025A (ko) * | 2021-07-12 | 2024-03-12 | 엔카르타, 인크. | Bcma-지시된 세포 면역요법 조성물 및 방법 |
| KR20240046926A (ko) * | 2021-07-23 | 2024-04-11 | 더 트러스티스 오브 컬럼비아 유니버시티 인 더 시티 오브 뉴욕 | Sars-cov-2, 그 변이체 및 관련 코로나바이러스를 강력하고 광범위하게 중화하는 단일클론항체의 특성 분석 및 사용 방법 |
| CA3227549A1 (en) | 2021-07-29 | 2023-02-02 | Cephalon Llc | Compositions and methods for anti-pacap antibodies |
| KR20240053607A (ko) * | 2021-08-27 | 2024-04-24 | 얀센 바이오테크 인코포레이티드 | 항-psma 방사성 접합체 및 이의 용도 |
| PE20240727A1 (es) | 2021-08-27 | 2024-04-15 | Janssen Biotech Inc | Anticuerpos anti-psma y usos de estos |
| WO2023034560A1 (en) * | 2021-09-02 | 2023-03-09 | Memorial Sloan-Kettering Cancer Center | Antigen recognizing receptors targeting cd33 and uses thereof |
| WO2023034564A2 (en) * | 2021-09-02 | 2023-03-09 | Memorial Sloan-Kettering Cancer Center | Anti-cd33 antibodies and uses thereof |
| WO2023034950A2 (en) * | 2021-09-03 | 2023-03-09 | Icahn School Of Medicine At Mount Sinai | Anti-hcmv antibodies and antigen-binding fragments thereof |
| EP4466284A2 (en) * | 2021-10-27 | 2024-11-27 | Twist Bioscience Corporation | Multispecific sars-cov-2 antibodies and methods of use |
| CN116333123A (zh) * | 2021-12-22 | 2023-06-27 | 宝船生物医药科技(上海)有限公司 | 抗tnfr2抗体及其用途 |
| JP2025509185A (ja) * | 2022-03-04 | 2025-04-11 | コアグラント・セラピューティクス・コーポレイション | 活性化されたタンパク質ｃに対するヒト抗体及びその使用 |
| JP2025534161A (ja) * | 2022-10-04 | 2025-10-14 | ミンク セラピューティクス， インコーポレイテッド | 線維芽細胞活性化タンパク質（ｆａｐ）ｃａｒインバリアントナチュラルキラーｔ細胞及びその使用 |
| KR20250173600A (ko) | 2023-03-17 | 2025-12-10 | 옥시토프 파마 비.브이. | 항-포스포콜린 항체 및 그 사용 방법 |
| CN116514998B (zh) * | 2023-05-12 | 2023-09-15 | 再少年(北京)生物科技有限公司 | 一种嵌合抗原受体、嵌合抗原受体-自然杀伤细胞及其在制备抗肿瘤药物中的应用 |
| TWI881873B (zh) * | 2023-07-03 | 2025-04-21 | 友生泰生醫股份有限公司 | 抗ｇｒｐ７８抗體及其應用 |
| WO2025015320A2 (en) * | 2023-07-12 | 2025-01-16 | Phenomic Ai | Anti-cthrc1 t cell engagers and methods of using the same |
| TW202525855A (zh) * | 2023-08-31 | 2025-07-01 | 美商艾克塞里克斯公司 | Ｉｌｔ２結合劑及其用途 |
| TW202515919A (zh) * | 2023-09-01 | 2025-04-16 | 比利時商艾托斯比利時公司 | 抗ｔｒｅｍ２抗體及使用方法 |
| WO2025081163A1 (en) * | 2023-10-13 | 2025-04-17 | GenCART, Inc. | Compositions for the treatment of cancer |
| US20250255980A1 (en) * | 2024-02-12 | 2025-08-14 | Mbrace Therapeutics, Inc. | Antibody-Drug Conjugates Against the Glucose-regulating Protein 78 (GRP78) |
| WO2025184137A1 (en) * | 2024-02-27 | 2025-09-04 | Adimab, Llc | Influenza antibodies and methods of use thereof |
| CN117986346B (zh) * | 2024-04-07 | 2024-07-26 | 中国人民解放军军事科学院军事医学研究院 | 一种tpo模拟肽及其应用 |
| WO2025217041A2 (en) * | 2024-04-09 | 2025-10-16 | Absos, Llc | Anti-april antibodies |
| CN120399078A (zh) * | 2025-05-08 | 2025-08-01 | 上海天泽云泰生物医药有限公司 | 靶向cd117的纳米抗体及其应用 |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4751180A (en) | 1985-03-28 | 1988-06-14 | Chiron Corporation | Expression using fused genes providing for protein product |
| US4935233A (en) | 1985-12-02 | 1990-06-19 | G. D. Searle And Company | Covalently linked polypeptide cell modulators |
| ATE102631T1 (de) | 1988-11-11 | 1994-03-15 | Medical Res Council | Klonierung von immunglobulin sequenzen aus den variabelen domaenen. |
| AU638762B2 (en) | 1989-10-05 | 1993-07-08 | Optein Inc | Cell-free synthesis and isolation of novel genes and polypeptides |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| CA2095633C (en) | 1990-12-03 | 2003-02-04 | Lisa J. Garrard | Enrichment method for variant proteins with altered binding properties |
| US5866344A (en) | 1991-11-15 | 1999-02-02 | Board Of Regents, The University Of Texas System | Antibody selection methods using cell surface expressed libraries |
| US20030036092A1 (en) | 1991-11-15 | 2003-02-20 | Board Of Regents, The University Of Texas System | Directed evolution of enzymes and antibodies |
| ES2341666T3 (es) | 1991-12-02 | 2010-06-24 | Medimmune Limited | Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos. |
| US5605793A (en) | 1994-02-17 | 1997-02-25 | Affymax Technologies N.V. | Methods for in vitro recombination |
| US6117679A (en) | 1994-02-17 | 2000-09-12 | Maxygen, Inc. | Methods for generating polynucleotides having desired characteristics by iterative selection and recombination |
| ES2176484T3 (es) | 1995-08-18 | 2002-12-01 | Morphosys Ag | Bancos de proteinas/(poli)peptidos. |
| US6562594B1 (en) | 1999-09-29 | 2003-05-13 | Diversa Corporation | Saturation mutagenesis in directed evolution |
| US5965408A (en) | 1996-07-09 | 1999-10-12 | Diversa Corporation | Method of DNA reassembly by interrupting synthesis |
| GB9701425D0 (en) | 1997-01-24 | 1997-03-12 | Bioinvent Int Ab | A method for in vitro molecular evolution of protein function |
| GB9703369D0 (en) | 1997-02-18 | 1997-04-09 | Lindqvist Bjorn H | Process |
| US6153410A (en) | 1997-03-25 | 2000-11-28 | California Institute Of Technology | Recombination of polynucleotide sequences using random or defined primers |
| ES2275304T3 (es) | 1997-04-04 | 2007-06-01 | Millennium Pharmaceuticals, Inc. | Nuevas composiciones de delta-3 humana y usos diagnosticos y terapeuticos para las mismas. |
| US20060122373A1 (en) | 1997-04-04 | 2006-06-08 | Millennium Pharmaceuticals, Inc. | Delta3, FTHMA-070, Tango85, Tango77, SPOIL,NEOKINE, Tango129 and integrin alpha subunit protein and nucleic acid molecules and uses thereof |
| US6664098B1 (en) | 1997-05-14 | 2003-12-16 | Asahi Kasei Kabushiki Kaisha | Differentiation inhibitory agent |
| CA2337492A1 (en) | 1998-07-27 | 2000-02-10 | Amgen Inc. | Delta-related polypeptides |
| US20020142374A1 (en) | 1998-08-17 | 2002-10-03 | Michael Gallo | Generation of modified molecules with increased serum half-lives |
| US20020102613A1 (en) | 1999-05-18 | 2002-08-01 | Hoogenboom Hendricus Renerus Jacobus Mattheus | Novel Fab fragment libraries and methods for their use |
| GB0008419D0 (en) | 2000-04-05 | 2000-05-24 | Bioinvent Int Ab | A method for invitro molecular evolution of antibody function |
| ATE363291T1 (de) | 2000-06-23 | 2007-06-15 | Bayer Schering Pharma Ag | Zusammensetzungen, die mit vegf/vegf und angiopoietin/tie rezeptor-funktionen interferieren |
| FR2816319B1 (fr) | 2000-11-08 | 2004-09-03 | Millegen | Utilisation d'adn polymerase mutagene pour la creation de mutations aleatoires |
| US20040253242A1 (en) * | 2000-12-05 | 2004-12-16 | Bowdish Katherine S. | Rationally designed antibodies |
| US7396917B2 (en) * | 2000-12-05 | 2008-07-08 | Alexion Pharmaceuticals, Inc. | Rationally designed antibodies |
| US20030022240A1 (en) | 2001-04-17 | 2003-01-30 | Peizhi Luo | Generation and affinity maturation of antibody library in silico |
| CA2457879A1 (en) | 2001-08-22 | 2003-03-06 | Galapagos Genomics N.V. | Modulators of bone homeostasis identified in a high-throughput screen |
| WO2003035842A2 (en) | 2001-10-24 | 2003-05-01 | Dyax Corporation | Hybridization control of sequence variation |
| JP2005526518A (ja) * | 2002-05-20 | 2005-09-08 | アブマクシス，インコーポレイティド | タンパク質ライブラリーのｉｎｓｉｌｉｃｏ作成と選択 |
| CA2488441C (en) | 2002-06-03 | 2015-01-27 | Genentech, Inc. | Synthetic antibody phage libraries |
| US20050079574A1 (en) | 2003-01-16 | 2005-04-14 | Genentech, Inc. | Synthetic antibody phage libraries |
| EP2824190A1 (en) * | 2003-09-09 | 2015-01-14 | Integrigen, Inc. | Methods and compositions for generation of germline human antibody genes |
| WO2005092925A2 (en) | 2004-03-24 | 2005-10-06 | Xencor, Inc. | Immunoglobulin variants outside the fc region |
| US8048418B2 (en) | 2004-10-29 | 2011-11-01 | Regeneron Pharmaceuticals, Inc. | Therapeutic methods for inhibiting tumor growth with combination of Dll4 antagonists and VEGF antagonists |
| EP1848672A4 (en) | 2005-02-01 | 2009-11-04 | Morphosys Ag | LIBRARIES AND METHOD FOR ISOLATING ANTIBODIES |
| ES2402576T3 (es) | 2005-11-14 | 2013-05-06 | Bioren, Inc. | Ultrahumanización de anticuerpos por generación y selección de bibliotecas cohorte y blast de cdr maduras previstas |
| NZ568739A (en) | 2005-12-16 | 2010-09-30 | Regeneron Pharma | Therapeutic methods for inhibiting tumor growth with delta-like ligand 4 antagonists |
| WO2007137616A1 (en) | 2006-05-30 | 2007-12-06 | Millegen | Highly diversified antibody libraries |
| CA2654000A1 (en) * | 2006-06-06 | 2008-05-22 | Genentech, Inc. | Anti-dll4 antibodies and methods using same |
| CA2654304A1 (en) * | 2006-06-06 | 2007-12-13 | Genentech, Inc. | Compositions and methods for modulating vascular development |
| CN101500605B (zh) | 2006-08-07 | 2014-04-30 | 瑞泽恩制药公司 | Dll4拮抗剂在治疗局部缺血性损伤中的用途 |
| EA018260B1 (ru) * | 2006-09-29 | 2013-06-28 | Онкомед Фармасьютикалз, Инк. | Антитела к дельта-подобному лиганду 4 человека и их применение |
| US20080100597A1 (en) | 2006-10-25 | 2008-05-01 | Macrovision Corporation | Method and apparatus to improve playability in overscan areas of a TV display |
| NO347649B1 (no) * | 2006-12-14 | 2024-02-12 | Regeneron Pharma | Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse. |
| WO2008091222A1 (en) | 2007-01-26 | 2008-07-31 | Bioinvent International Ab | Dll4 signaling inhibitors and uses thereof |
| GB0709333D0 (en) * | 2007-05-15 | 2007-06-20 | Smart Targeting Ltd | Binding protein |
| CA2742968C (en) | 2008-11-07 | 2020-06-09 | Fabrus Llc | Combinatorial antibody libraries and uses thereof |
-
2009
- 2009-11-04 CA CA2742968A patent/CA2742968C/en not_active Expired - Fee Related
- 2009-11-04 US US13/128,236 patent/US9403904B2/en not_active Expired - Fee Related
- 2009-11-04 AU AU2009313560A patent/AU2009313560B2/en not_active Ceased
- 2009-11-04 US US13/128,219 patent/US9221902B2/en active Active
- 2009-11-04 DK DK09748671.6T patent/DK2356270T3/da active
- 2009-11-04 WO PCT/US2009/063303 patent/WO2010054010A1/en not_active Ceased
- 2009-11-04 JP JP2011535649A patent/JP5882058B2/ja not_active Expired - Fee Related
- 2009-11-04 AU AU2009313551A patent/AU2009313551B2/en not_active Ceased
- 2009-11-04 WO PCT/US2009/063299 patent/WO2010054007A1/en not_active Ceased
- 2009-11-04 EP EP09748671.6A patent/EP2356270B1/en active Active
- 2009-11-04 CA CA2742969A patent/CA2742969A1/en not_active Abandoned
- 2009-11-04 JP JP2011535651A patent/JP2012508017A/ja active Pending
- 2009-11-04 EP EP09748672A patent/EP2356146A1/en not_active Withdrawn
-
2015
- 2015-08-10 JP JP2015157842A patent/JP2016040246A/ja active Pending
- 2015-12-04 US US14/959,940 patent/US10774138B2/en active Active
-
2016
- 2016-02-03 JP JP2016018531A patent/JP2016127850A/ja active Pending
- 2016-07-07 AU AU2016204719A patent/AU2016204719A1/en not_active Abandoned
-
2018
- 2018-03-06 AU AU2018201622A patent/AU2018201622A1/en not_active Abandoned
-
2020
- 2020-08-25 US US17/002,749 patent/US20200399359A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012508017A5 (OSRAM) | ||
| JP2023129543A5 (OSRAM) | ||
| IL302078A (en) | Anti-ccr8 monoclonal antibodies and uses thereof | |
| RU2019120079A (ru) | Стабильные и растворимые антитела, ингибирующие vegf | |
| JP2020152735A5 (OSRAM) | ||
| JP2008500815A5 (OSRAM) | ||
| JP2020079252A5 (OSRAM) | ||
| TWI769537B (zh) | 標靶ｂｃｍａ的抗體、雙專一性抗體及其用途 | |
| JP2010516229A5 (OSRAM) | ||
| US9556275B2 (en) | Combination therapy using anti-C-met antibody and anti-ang-2 antibody | |
| JP2023070678A5 (OSRAM) | ||
| JP2017500028A5 (OSRAM) | ||
| JP2011518125A5 (OSRAM) | ||
| KR102078292B1 (ko) | 신규한 항 c-Met 항체 및 이의 용도 | |
| JP2010534478A5 (OSRAM) | ||
| HRP20171690T1 (hr) | Antitijela koja se vežu za humani cgrp receptor | |
| KR102349370B1 (ko) | 인간화 또는 친화도 성숙된 항 앤지오포이에틴-2 항체 및 그의 용도 | |
| HRP20120611T1 (hr) | Anti-il-23p19 antitijela proizvedena genetiäśkim inžinjerstvom | |
| JP2020517249A5 (OSRAM) | ||
| JP2014530017A5 (OSRAM) | ||
| ME03394B (me) | Antidllз-antitelo-pbd konjugati i nihovа upotreba | |
| IL290591B1 (en) | Antibody drug conjugates (adc) that bind to 191p4d12 proteins | |
| ME02705B (me) | Inženjerisana anti-il-23 antitela | |
| RU2009115363A (ru) | Антагонисты рецепторов для лечения метастатического рака | |
| HRP20160584T1 (hr) | Novo anti-dr5 antitijelo |